Sight Sciences Inc (SGHT)

Dec 19, 2024, 4:05 PM EST - 4 weeks ago

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

Nov 19, 2024, 4:05 PM EST - 2 months ago

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 9, 2024, 1:32 PM EST - 2 months ago

Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 6:58 AM EST - 2 months ago

Top 3 Health Care Stocks You'll Regret Missing In November

CMPS PACS

Oct 17, 2024, 4:05 PM EDT - 3 months ago

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

Oct 14, 2024, 4:05 PM EDT - 3 months ago

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

Aug 20, 2024, 4:05 PM EDT - 5 months ago

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Aug 3, 2024, 3:12 AM EDT - 6 months ago

Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 4:05 PM EDT - 6 months ago

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

Jun 10, 2024, 4:05 PM EDT - 7 months ago

Sight Sciences Announces the Release of its First Sustainability Report

May 28, 2024, 4:05 PM EDT - 8 months ago

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

May 28, 2024, 8:30 AM EDT - 8 months ago

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

May 5, 2024, 1:58 AM EDT - 9 months ago

Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 9 months ago

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Apr 29, 2024, 8:05 AM EDT - 9 months ago

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

Apr 18, 2024, 4:05 PM EDT - 9 months ago

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

Apr 10, 2024, 4:05 PM EDT - 10 months ago

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2

Apr 2, 2024, 4:05 PM EDT - 10 months ago

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Mar 26, 2024, 4:05 PM EDT - 10 months ago

Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

Mar 7, 2024, 10:56 PM EST - 11 months ago

Sight Sciences, Inc. (SGHT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:05 PM EST - 11 months ago

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

Feb 22, 2024, 4:05 PM EST - 11 months ago

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

Feb 14, 2024, 4:05 PM EST - 1 year ago

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

Jan 23, 2024, 4:05 PM EST - 1 year ago

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

Jan 8, 2024, 4:05 PM EST - 1 year ago

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Dec 28, 2023, 9:15 AM EST - 1 year ago

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

Dec 18, 2023, 4:05 PM EST - 1 year ago

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Dec 8, 2023, 8:05 AM EST - 1 year ago

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

Nov 11, 2023, 12:38 PM EST - 1 year ago

Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 1 year ago

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

Oct 24, 2023, 4:05 PM EDT - 1 year ago

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

Oct 19, 2023, 4:05 PM EDT - 1 year ago

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

Oct 12, 2023, 4:05 PM EDT - 1 year ago

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting

Oct 3, 2023, 8:30 AM EDT - 1 year ago

Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

Sep 21, 2023, 5:11 AM EDT - 1 year ago

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

SCLX TNYA TSBX

Sep 12, 2023, 7:04 AM EDT - 1 year ago

Sight Sciences' stock tumbled 32% premarket after revenue warning

Sep 11, 2023, 4:06 PM EDT - 1 year ago

Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023

Sep 11, 2023, 4:05 PM EDT - 1 year ago

Sight Sciences Appoints Matt Link as Chief Commercial Officer

Aug 30, 2023, 4:05 PM EDT - 1 year ago

Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference

Aug 7, 2023, 2:00 PM EDT - 1 year ago

Sight Sciences: Staying Bullish After Q2 Results Beat

Aug 6, 2023, 7:32 AM EDT - 1 year ago

Sight Sciences, Inc. (SGHT) Q2 2023 Earnings Call Transcript

Aug 3, 2023, 4:05 PM EDT - 1 year ago

Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

Jul 20, 2023, 8:30 AM EDT - 1 year ago

Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye

Jun 21, 2023, 8:30 AM EDT - 1 year ago

Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)

Jun 9, 2023, 4:05 PM EDT - 1 year ago

Sight Sciences Announces Addition of New Director Catherine Mazzacco

May 30, 2023, 5:00 PM EDT - 1 year ago

Sight Sciences: Recent Stock Price Pullback Is Unwarranted

May 23, 2023, 8:30 AM EDT - 1 year ago

Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical Syste

May 7, 2023, 7:58 AM EDT - 1 year ago

Sight Sciences, Inc. (SGHT) Q1 2023 Earnings Call Transcript

May 6, 2023, 11:30 AM EDT - 1 year ago

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

Apr 26, 2023, 4:05 PM EDT - 1 year ago

Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference